| 引用本文: | 虞海红,陈建.FOLFOX与XELOX方案治疗晚期结直肠癌毒性表现的系统评价[J].中国现代应用药学,2013,30(11):1245-1248. |
| YU Haihong,CHEN Jian .Toxicity of FOLFOX versus XELOX as Chemotherapy for Metastatic Colorectal Cancer: a Meta-analysis[J].Chin J Mod Appl Pharm(中国现代应用药学),2013,30(11):1245-1248. |
|
| 摘要: |
| 目的 系统评价氟尿嘧啶/亚叶酸钙联合奥沙利铂(FOLFOX方案)与卡培他滨联合奥沙利铂(XELOX方案)治疗晚期结直肠癌毒性差异，为晚期结直肠癌“个体化”药物治疗方案选择提供依据。方法 检索PubMed、Embase、Cochrane、CNKI等数据库和ASCO会议文献，采用系统评价的方法进行系统评价。结果 共10个研究4 084例患者纳入毒性的系统评价，结果表明XELOX方案在手足综合症(RR=3.60，95% CI：2.27~5.72，P<0.000 1)、血小板减少(RR=1.83，95% CI：1.36~2.48，P<0.000 1)发生率高于FOLFOX方案，在中性粒细胞减少(RR=0.24，95% CI：0.14~0.41，P<0.000 1)发生率低于FOLFOX方案；恶心、呕吐、腹泻以及神经毒性发生率两方案无统计学差异。结论 在晚期结直肠癌治疗中，FOLFOX方案与XELOX方案在毒性反应方面各有特点，应结合患者具体情况，选择最宜治疗方案。 |
| 关键词: 晚期结直肠癌 氟尿嘧啶 卡培他滨 奥沙利铂 系统评价 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Toxicity of FOLFOX versus XELOX as Chemotherapy for Metastatic Colorectal Cancer: a Meta-analysis |
|
YU Haihong1, CHEN Jian 2
|
|
1.Jiangcun&Wenxin Community Health Service Center in the Westlake District, Hangzhou 310030, China;2.The First Affiliate Hospital, College of Medicine, Zhejiang University, Hangzhou 310012, China
|
| Abstract: |
| OBJECTIVE To compare toxicities of fluorouracil/folinic acid plus oxaliplatin(FOLFOX) versus capecitabine plus oxaliplatin (XELOX) as chemotherapy for metastatic colorectal cancer. METHODS PubMed database, EMbase database, Cochrane, CNKI database and ASCO meeting article were searched, and a meta-analysis was conducted. RESULTS Ten studies involving 4 084 patients were included for systematic reviews of toxicity. The incidence of neutropenia (RR=0.24, 95% CI: 0.14-0.41, P<0.000 1) was higher in FOLFOX group, hand-foot syndrome (RR=3.60, 95% CI: 2.27-5.72, P<0.000 1) and thrombocytopenia(RR=1.83, 95% CI: 1.36-2.48, P<0.000 1) was higher in XELOX group. Nausea, vomiting, diarrhea and neuropathy were not significantly different between the two groups(P>0.05). CONCLUSION In metastatic colorectal cancer patients, FOLFOX and XELOX have their own advantages and disadvantages concerning with toxic reactions. |
| Key words: metastatic colorectal cancer fluorouracil capecitabine oxaliplatin Meta-analysis |
